The use and application of special techniques in assessing melanocytic tumours

References

• Marghoob AA, Swindle LD, Moricz CZ, et al. Instruments and new technologies for the in vivo diagnosis of melanoma. J Am Acad Dermatol 2003; 49: 777–97.
   PubMed Web of Science ®Google Scholar
• Busam KJ, Charles C, Lohmann CM, Marghoob A, Goldgeier M, Halpern AC. Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy. Melanoma Res 2002; 12: 349–55.
   PubMed Web of Science ®Google Scholar
• Busam KJ, Hester K, Charles C, et al. Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch Dermatol 2001; 137: 923–9.
   PubMed Web of Science ®Google Scholar
• Gaynor R, Herschman HR, Irie R, et al. S100 protein: a marker for human malignant melanomas? Lancet 1981; 1(8225): 869–71.
   PubMed Web of Science ®Google Scholar
• McNutt NS. The S100 family of multipurpose calcium-binding proteins. J Cutan Pathol 1998; 25: 521–9.
   PubMed Web of Science ®Google Scholar
• Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195–203.
   PubMed Web of Science ®Google Scholar
• Wood WS, Tron VA. Analysis of HMB-45 immunoreactivity in common and cellular blue nevi. J Cutan Pathol 1991; 18: 261–3.
   PubMed Web of Science ®Google Scholar
• Bergman R, Dromi R, Trau H, Cohen I, Lichtig C. The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatopathol 1995; 17: 542–6.
   Google Scholar
• Bonetti F, Chiodera PL, Pea M, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol 1993; 17: 1092–102.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Scl USA 1994; 91: 3515–9.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lympho-cytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35–42.
   PubMed Web of Science ®Google Scholar
• Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93: 5915–9.
   PubMed Web of Science ®Google Scholar
• Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens Mart-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J Immunother Emphasis Tumor Immunol 1996; 19: 192–205.
   PubMed Web of Science ®Google Scholar
• Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentia-tion marker. Adv Anat Pathol 1999; 6: 12–8.
   PubMed Web of Science ®Google Scholar
• Smith-Zagone MJ, Prieto VG, Hayes RA, et al. HMB-45 and Mart-1 expression within giant cells in an atypical fibroxanthoma: a case report. J Cutan Pathol 2004; 31: 284–6.
   Google Scholar
• Yan S, Brennick JB. False-positive rate of immunoperoxidase stains for Mart-1/Melan-A in lymph nodes. Am J Surg Pathol 2004; 28: 596–600.
   PubMed Web of Science ®Google Scholar
• Chen YT, Stockert E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125–9.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Iversen K, Coplan K, et al. T311-an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract 2000; 196: 235–42.
   PubMed Web of Science ®Google Scholar
• Prasad ML, Jungbluth AA, Iversen K, et al. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol 2001; 25: 782–7.
   PubMed Web of Science ®Google Scholar
• Widlund HR, Fisher DE. Microphthalmia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003; 19: 3035–41.
   Web of Science ®Google Scholar
• Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197–204.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of meta-static melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001; 25: 205–11.
   PubMed Web of Science ®Google Scholar
• Shibahara S, Takeda K, Yasumoto K, et al. Microphthalmia-associated transcription factor (MITF): multiplicity in structure, function, and regulation. J Investig Dermatol Symp Proc 2001; 6: 99–104.
   PubMedGoogle Scholar
• Vijayasaradhi S, Houghton AN. Purification of an autoantigenetic 75 kDa human melanosomal glycoprotein. Int J Cancer 1991; 21: 298–303.
   Web of Science ®Google Scholar
• Dean NR, Brennan J, Haynes J, et al. Immunohistochemical labeling of normal melanocytes. Appl Immunohistochem Mol Morphol 2002; 10: 199–204.
   PubMedGoogle Scholar
• Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol 2003; 16: 481–90.
   PubMed Web of Science ®Google Scholar
• Mackie RM, Campbell I, Turbitt ML. Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol 1984; 37: 367–72.
   Google Scholar
• Karimipour DJ, Lowe L, Su L, et al. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? J Am Acad Dermatol 2004; 50: 759–64.
   PubMed Web of Science ®Google Scholar
• Lohmann CM, Iversen K, Jungbluth AA, et al. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am J Surg Pathol 2002; 26: 1351–7.
   PubMed Web of Science ®Google Scholar
• Li LX, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2000; 22: 489–95.
   PubMed Web of Science ®Google Scholar
• Li LX, Crotty KA, Scolyer RA, et al. Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions: a study of DNA microdensitometry, karyometry, argyrophilic staining of nuclear organizing regions and MIB01-Ki67. Melanoma Res 2003; 13: 581–6.
   PubMed Web of Science ®Google Scholar
• Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4: 341–5.
   PubMed Web of Science ®Google Scholar
• Bastian BC. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. Recent Results Cancer Res 2002; 160: 92–9.
   PubMedGoogle Scholar
• Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001; 19: 568–76.
   PubMed Web of Science ®Google Scholar